Head to Head Review: Quanterix (NASDAQ:QTRX) & OmniAb (NASDAQ:OABI)

OmniAb (NASDAQ:OABI) and Quanterix (NASDAQ:QTRX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership and risk.

Valuation & Earnings

This table compares OmniAb and Quanterix”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OmniAb	$18.67 million	34.74	-$64.78 million	($0.36)	-12.44
Quanterix	$153.17 million	0.77	-$107.15 million	($2.63)	-0.95

OmniAb has higher earnings, but lower revenue than Quanterix. OmniAb is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares OmniAb and Quanterix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OmniAb	-115.12%	-16.59%	-14.82%
Quanterix	-80.25%	-26.09%	-19.03%

Analyst Ratings

This is a summary of recent ratings and recommmendations for OmniAb and Quanterix, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OmniAb	1	0	2	0	2.33
Quanterix	1	2	0	0	1.67

OmniAb currently has a consensus price target of $11.00, indicating a potential upside of 145.54%. Quanterix has a consensus price target of $3.00, indicating a potential upside of 20.00%. Given OmniAb’s stronger consensus rating and higher possible upside, equities analysts plainly believe OmniAb is more favorable than Quanterix.

Insider & Institutional Ownership

72.1% of OmniAb shares are owned by institutional investors. Comparatively, 86.5% of Quanterix shares are owned by institutional investors. 9.8% of OmniAb shares are owned by company insiders. Comparatively, 1.5% of Quanterix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility and Risk

OmniAb has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Quanterix has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500.

Summary

OmniAb beats Quanterix on 9 of the 14 factors compared between the two stocks.

About OmniAb

OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.